The human host has evolved elaborate protection mechanisms to prevent infection from the billions of microorganisms to which it host is exposed and is home. One of these systems, complement, is an evolutionary ancient arm of innate immunity essential for combatting bacterial infection. Complement permits the efficient labelling of bacteria with opsonins, supports phagocytosis, and facilitates phagocyte recruitment to the site of infection through the production of chemoattractants. However, it is by no means perfect, and certain organisms engage in an evolutionary arms race with the host where complement has become a major target to promote immune evasion. Streptococcus pyogenes is a major human pathogen that causes significant morbidity and mortality globally. S. pyogenes is also a member of an elite group of bacterial pathogens possessing a sophisticated arsenal of virulence determinants capable of interfering with complement. In this review, we focus on these complement evasins, their mechanism of action, and their importance in disease progression. Finally, we highlight new therapeutic options for fighting S. pyogenes, by interfering with one of its main mechanisms of complement evasion.
Introduction
The Gram-positive bacterium, Streptococcus pyogenes, also referred to as group A streptococcus (GAS), is an exclusively human pathogen listed in the top 10 infectious causes of human mortality [1] . S. pyogenes primarily colonises the epithelial surface of the nasopharynx and skin and, in most cases, results in asymptomatic carriage. Under certain conditions and observed more frequently in specific serotypes, S. pyogenes can cause a suite of diseases, from superficial to life-threating infections, as well as post-infection immune-related diseases [2] . Worryingly, S. pyogenes invasive infection has a high mortality ranging between 10 and 30%, which results in approximately 600,000 deaths globally, mostly occurring in resourcelimited regions [1, 2] . S. pyogenes isolates are commonly typed according to the variable 5′ region of the emm gene coding for the M protein, a major virulence determinant [3] . Epidemiological studies have illustrated that GAS M type is intimately correlated with both clinical disease presentations and geographical location where M type diversity is significantly reduced among invasive isolates, in comparison to those causing superficial, self-limiting diseases [4] .
S. pyogenes is an excellently equipped pathogen harbouring a multitude of virulence determinants and genetic regulators that facilitate its associated diverse infection profile [2] . S. pyogenes pathogenesis occurs by step-cooperating to mediate a specific task, such as evading complement which will be the focus of this review.
Complement consists of > 35 soluble and immobilised proteins, receptors, and regulators, playing central roles in immune surveillance, clearance of toxic materials, activation of the adaptive immune response, and defence against infection [5] . Bacterial activation of complement proceeds in a well-defined, tightly regulated cascade of enzymatic reactions originating from 3 different pathways: the classical pathway (CP), the lectin pathway (LP), and the alternative pathway (AP) [5] . Activation of the CP begins with the recognition and binding of microbial surfaces by the immunoglobulins, IgM and/or IgG, followed by recognition and binding by C1q via Ig Fc regions [6] . Additionally, members of the pentaxin family, which interact with specific structures on bacterial surfaces, also Table 1 ). Despite the capsule (5) not being a defined single molecule, it is an important factor contributing significantly to virulence. GAPDH (6) is not a traditional surface protein but is bound to the surface and depletes C5a there. Vitronectin-binding protein (8) has not been described as affecting complement, but vitronectin itself is known to inhibit MAC formation; to highlight this, a question mark was added to the schema. CP, classical pathway; LP, lectin pathway; AP, alternative pathway. provide binding sites for C1q and activate the CP [6] . The LP is activated through recognition of carbohydrate ligands displayed on the microbial surface via mannosebinding lectins (MBLs), ficolins (1-3), and collectin-11 [5] . Both C1q and LP recognition molecules form complexes with a set of distinct serine proteases, C1r/s, and MBL-associated serine proteases (MASPs), respectively. Binding of CP and LP recognition molecules to their respective ligands results in the activation of serine proteases which cleave C4 and C2 to generate the C3 convertase enzyme, C4bC2a [7] . In contrast to the CP and LP, the AP represents a constitutively active system. Spontaneous hydrolysis of a thioester bond within C3 generates a conformationally altered C3 molecule called C3(H 2 O), capable of interaction with factor B (CFB). Binding of CFB to C3(H 2 O) alters the CFB structure, resulting in the cleavage of CFB by the serine protease factor D (CFD) into the products Ba and Bb. Bb interacts with C3(H 2 O) which can cleave C3 into cleavage products C3a and C3b in a similar fashion to the classical C3 convertase. Importantly, deposited C3b generated from any of the 3 pathways can interact with CFB and be subsequently processed by CFD, resulting in the formation of the AP C3 convertase, C3bBb, which rapidly converts more C3 molecules into C3b and C3a, serving as an amplification loop for the whole complement system [6] . Labelling of bacteria with C3b and the release of anaphylatoxin, C3a, are required for efficient phagocytosis and bacterial eradication. The alternative C3 convertase in amplifying C3b opsonisation also leads to the generation of the C5 convertases, which cleave soluble C5 into C5a, a potent leukocyte chemoattractant, and C5b, an integral component of the membrane attack complex (MAC) [5] . Following interaction with the complement components C6-9, the MAC may then insert into the cell membrane of susceptible bacteria, resulting in cell lysis and death [5] .
Complement Evasion Mechanisms of S. pyogenes
Host cells are protected from complement by a set of membrane-bound or soluble inhibitors [6, 8] . Membrane-bound complement regulators include decay-accelerating factor (DAF/CD55), membrane cofactor protein (MCP/CD46), and complement C3b/C4b receptor 1 (CR1/CD35) [7, 8] . DAF disrupts both the classical/lectin and alternative C3 convertases by promoting subunit dissociation of generated C3 convertases and inhibiting the formation of new convertases. MCP serves as a cofactor for C3b and C4b cleavage by the plasma serine protease, factor I (CFI). C4b-binding protein (C4BP) and factor H (FH) are soluble, negative regulates targeting the classi- cal/lectin and alternative convertases, respectively, serving as cofactors for CFI-mediated complement inhibition [7, 8] . CR1 also exhibits cofactor activity for CFI, promoting the cleavage of C3b to proteolytically inactive iC3b, with iC3b further cleaved into C3c and C3dg. The formation of the MAC is also regulated by membrane-bound CD59, which prevents association of C9 with C5b-8, while 2 plasma proteins, vitronectin and clusterin, prevent the interaction of C5b-7 with C9 [8] .
In order to survive within the mammalian host, all major human pathogens have evolved specific virulence determinants that target several mechanisms of host immunity. Altering complement activity is no exception, whereby examples of bacterial immune evasins targeting every step of complement have been reported [9] . In this review, we document how S. pyogenes has become a master of complement evasion, interfering with virtually all aspects of complement activation, utilising both surfaceexpressed and secreted complement evasins.
Surface-Bound Virulence Factors
S. pyogenes expresses a broad variety of surface-bound virulence factors (online suppl. Table 1 ; Fig. 1 ), allowing it to efficiently escape immune recognition and prevent phagocytic uptake. One of the most prominent and wellstudied virulence factors of S. pyogenes are the M proteins and M-related proteins.
M Protein Family
Several bacteria, including S. pyogenes, have evolved methods to recruit C4BP and FH, the 2 major soluble complement regulatory proteins, to their surface. Once bound, both C4BP and FH serve as cofactors to the serum protease (CFI) which inactivates deposited C4b and C3b, respectively. Additionally, C4BP accelerates the decay of the CP/LP C3 convertase, whereas FH is responsible for the decay of the AP convertase. As a result, S. pyogenes covered with complement inhibitors has less C3b deposited on its surface than strains that cannot bind these inhibitors [10] .
The members of the M protein family, i.e., M protein itself, M-like, and M-related proteins (e.g., protein H, Enn, Arp, or Sir), are amongst the surface proteins responsible for this complement evasion strategy. M proteins are commonly used to classify GAS strains; to date, > 200 different groups have been identified [11] . These proteins possess direct antiphagocytic properties and play a major role in mediating the adherence and invasion of host cells ( Fig. 1 (1) ) [12, 13] . Furthermore, and probably as important, these virulence factors can bind a broad variety of host proteins, namely C4BP and FH, fibrinogen, fibrin, plasmin(-ogen), neural-cell adhesion molecule (NCAM), and different immunoglobulins [14] [15] [16] [17] .
However, preventing complement activation is not only achieved through bound complement inhibitors. It has been shown that the recruitment of fibrinogen and its cleavage products also reduce complement activation. The mechanism here is still not entirely clear, but it is proposed that the binding of fibrinogen may prevent phagocytes from recognising deposited C3b due to sterical hindrance [16] . Additionally, fibrinogen inhibits the formation of the classical/lectin C3 convertase [18] . Thus, preventing complement activation via the CP seems to be of importance to S. pyogenes. This is achieved by binding C4BP or fibrinogen, which both inhibit the CP. Interestingly, M proteins binding C4BP usually do not bind fibrinogen and vice versa, suggesting that the 2 proteins amend each other in the protection of S. pyogenes.
Another way to counteract osponisation is by the recruitment of the host serum protease plasmin, to directly inactivate deposited C3b. S. pyogenes binds and recruits plasminogen directly at the cell surface, which subsequently becomes activated by the host activators urokinase and tissue plasminogen activator. Interestingly, it has been shown that to protect against C3b-mediated phagocytosis, the accumulation of plasminogen to the bacterial surface (and not plasmin) was the critical factor [17] . Although streptokinase ( Fig. 2 (F) ) can convert plasminogen to plasmin, which then degrades C3b to degrade surface-bound C3b, streptokinase is dispensable. The role of secreted streptokinase in complement evasion is therefore not fully understood, but its role as a plasminogen activator is critical for bacterial dissemination and invasive disease [19] .
The M1T1 subclone of M1 serotype is a highly virulent, globally disseminated strain, correlated with severe invasive GAS diseases such as necrotising fasciitis and streptococcal toxic shock-like syndrome (STTS). One of the key features of this strain is the co-expression of M protein and another member of the M-protein family, protein H. More than 30% of all M1 strains are supposed to express protein H. The gene for protein H is encoded adjacent to the M protein and, presumably, has evolved by gene duplication [20] . Similar to M proteins, protein H also presents a coiled-coil dimer structure with a heptad repeat pattern [21] . It can bind to a variety of human serum proteins, such as albumin, the complement inhibitors FH and C4BP, and IgG, via their Fc portion [12, 14, 15, 22] . Interestingly, certain ligands such as IgG or albumin as well as temperature can influence the structure of protein H and the M proteins [21, 23] . For example, the binding of serum proteins is dependent on the dimeric state of protein H. Recently, we showed that C4BP binding to S. pyogenes is enhanced by human IgG [24] . Monomeric protein H does not bind C4BP and other ligands, but as soon as the protein forms a homodimer, ligands can bind. The formation of homodimers is supported by temperatures < 37 ° C. Although IgG cannot induce dimerisation, at high temperatures, it can stabilise alreadyformed dimers and prevent monomerisation, even at temperatures as high as 41 ° C. The increased C4BP binding results directly in decreased opsonophagocytosis and a dramatic increase in mortality in experimental streptococcal infections in mice.
FH-Binding Proteins: FbaA and Scl1
In addition to the M protein family, other cell surfaceexpressed proteins participate in complement evasion. The fibronectin-binding protein FbaA ( Fig. 1 (2) ) and streptococcal collagen-like protein 1 (Scl1) (Fig. 1 (3) ) also mediate the recruitment of FH [25, 26] . The 40.5-kDa protein FbaA was initially identified as a fibronectinbinding protein and was shown to be important in adhesion and pathogenesis. An fbaA mutant showed significantly less lethality in mice, most likely due to the lack of fibrinogen binding causing reduced adherence and increased complement activation [25] .
Scl1, a 44.5-kDa protein, binds FH, FH-related protein 1 (CFHR1), α2β1 integrins, low-density lipoprotein (LDL), fibronectin, laminin, and the thrombin-activatable fibrinolysis inhibitor [26] . Interestingly, Scl1 binds FH via the conserved C-terminal domains 18-20, while all other FH-binding proteins recruit FH via the more Nterminal domains 5-7 [27] . The protective effect for complement evasion is mediated through FH and FHL1 or CFHR1, similar to the M protein family. As a result, there is no direct interaction between the 2 virulence factors and the complement effectors.
Sfb1/PrtF1 and the Capsule: Virulence Factors Directly Affecting Complement Deposition
Not all virulence factors require the acquisition of a host regulator to affect complement activation. For example, fibronectin-binding protein Sfb1/PrtF1 seems to directly reduce C3b deposition on S. pyogenes ( Fig. 1 (4) ) [28] . Sfb1/PrtF1 causes increased invasion of epithelial cells and confers resistance to phagocytosis. The mechanism of how the protein interferes with C3b deposition is not completely clear, but it has been speculated that the protein itself, or when bound to fibronectin, results in sterical hindrance, preventing efficient C3b deposition. Another example is the hyaluronic acid capsule, which also reduces C3b deposition and confers resistance to phagocytosis [29] (Fig. 1 (5) ). It has been speculated that the hyaluronate capsule may serve as a physical barrier, which would prevent the phagocyte receptor from interacting with the underlying C3b deposited directly on the cell wall.
ScpA and GAPDH: Anaphylatoxin-Inactivating Evasins
A completely different but equally important target is the anaphylatoxin C5a, which recruits and activates professional phagocytes to the site of infection. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a pivotal enzyme of glycolysis but has been recently described as a complement evasin. It is classically found as a cytosolic enzyme but was recently shown to have alternative moonlighting functions. It has been observed both on the bacterial surface and in culture supernatant, where it binds and sequesters C5a, preventing neutrophil influx ( Fig.1  (6) ) [30] . The classical C5a peptidase, ScpA ( Fig. 1 (7) ), inactivates C5a and suppresses neutrophil activation. ScpA is a member of the subtilisin-like serine protease family and is known to promote bacterial persistence and dissemination in mouse infection models. Recently, ScpA was also found to inactivate both C3 and C3a [31] . After cleavage, abnormally sized C3a and C3b molecules are formed, which cannot attract neutrophils or be deposited on the bacterial surface, respectively. Importantly, both GAPDH and ScpA work in concert for the efficient cleavage of surface-bound C5a [30] .
Secreted Complement Evasins of GAS
The S. pyogenes secretome consists of a multitude of proteins which disrupt innate immune responses. For complement evasion, these factors can target both complement components and/or immunoglobulins for degradation or bind and interfere with Fc recognition by professional phagocytes. In both cases, complement and antibody-mediated phagocytosis are impaired.
Cysteine Proteinase
The cysteine proteinase, SpeB, is classically considered as the major secreted virulence factor of S. pyogenes. The gene, speB, is chromosomally encoded in virtually all se-DOI: 10.1159/000492944 quenced strains, and codes for an inactive 40-kDa protein which is autocatalytically processed into a 28-kDa broad spectrum cysteine proteinase [32] .
Several lines of evidence point to the importance of SpeB in GAS pathogenicity. Mutagenesis of speB results in decreased skin lesions, tissue destruction, dissemination, and lethality in murine models of infection [33] . Moreover, speB is expressed during infection, humans generate anti-SpeB antibodies, and acute-phase sera from patients suffering from GAS bacteraemia have lower SpeB antibodies than patients with uncomplicated tonsillitis [2, 34] . Furthermore, a recent study analysing > 9,000 GAS strains highlighted that the overwhelming majority of isolates derived from serotypes associated with invasive disease secrete SpeB [35] .
At the heart of SpeB activity is the non-restrictive substrate specificity permitting the hydrolysis of proteins ( Fig. 2 (A) ) [32] . SpeB importance as a virulence factor is primarily based on its ability to target and inactivate many different host and bacterial proteins, thereby modulating both innate and adaptive immunity and virulence regulation. The proteolytic activity of SpeB on complement was shown in 2 studies [36, 37] , both illustrating that SpeB targets the central C3 molecule and results in degradation. SpeB-treated serum diminishes CP, LP, and AP activation, and prevents activation and killing by human neutrophils by interfering with complement deposition. Complementing these observations, in vitro human neutrophil and blood survival models and mouse models of infection have shown that an speB mutant has reduced survival [36, 37] . Interestingly, the inhibition of iC3b interaction with CD11b/CD18 in human immune sera permitted GAS growth compared to Fc blocking, confirming the importance of iC3b deposition for controlling GAS infection [38] .
SpeB also targets several other complement components, i.e., C1 inhibitor (C1-INH), C2, C4, C5a, C6, C7, C8, and C9 ( Fig. 2 (A) ) [39] . Degradation of C1-INH prevents the inhibition of serine proteases of the CP (C1s and C1r) and LP (MASPs) which may result in C4 and C2 cleavage away from the bacterial surface, analogous to the Vag8-mediated complement evasion of Bordetella pertussis [40] . Proteolytic inactivation of the above complement components will also likely impact on C3 convertase and membrane attack formation and chemotaxis, thereby disrupting innate immunity.
Additionally, SpeB targets the alternative pathway by degrading the positive regulator, properdin [41] . Properdin acts as a local initiator for the AP, by stabilising the alternative C3 convertase, and it is thus critical for AP activation and C3b amplification on the bacterial surface [5] . Disruption of properdin destabilises this complex, disrupting efficient phagocytosis and phagocyte recruitment that permit bacterial dissemination.
Classically, SpeB was thought to be an important IgGdegrading enzyme; however, recent data suggests that SpeB only cleaves immunoglobulins when they are in a reduced state, i.e. not under physiological conditions [42] . Importantly, GAS also secretes 2 dedicated IgG-degrading enzymes, discussed in the following section.
It is important to note that the broad substrate specificity of SpeB permits the degradation of a whole suite of host proteins, not restricted to the complement system, and the cumulative effect of this activity is most likely the essential feature of GAS pathogenicity.
IdeS/Mac-1, Mac-2, and EndoS IgG Degradation and Interference
IgG molecules are the most abundant class of antibodies in human serum and represent a critical element in the fight against infection by activating the complement system through IgG-Fc-C1q-binding and mediating efficient opsonophagocytosis via interaction with Fcγ receptors on phagocytes.
To combat this host response, S. pyogenes secretes 3 main immunoglobulin-degrading enzymes, known as IdeS/Mac-1, Mac-2, and EndoS. Two study groups independently identified a non-SpeB protease with efficient IgG-degrading activity and a secreted protein with homology to the α-subunit of human Mac-1 (CD11b/CD18, CR3), resulting in the IdeS/Mac-1 nomenclature [43, 44] . IdeS/Mac-1 is a 35-kDa cysteine endopeptidase with strict specificity to IgG and is present in all strains in 1 of 2 allelic variants [45] . IdeS/Mac-1 interaction with IgG results in proteolytic cleavage at a specific site present in the lower region of the heavy chain between 2 glycine residues (G236 and G237), efficiently inhibiting complement-binding and Fc recognition (Fig. 2 (B) ) [44] . Hydrolysis of streptococcal IgG antibodies by IdeS/Mac-1 produces high amounts of circulating F(ab') 2 fragments, which can rebind to the bacterial surface but cannot mediate complement activation or immune cell signaling, thus exerting a protective effect [45] . IdeS/Mac-1 also contains an Arg-Gly-Asp (RGD) motif, a sequence commonly associated with integrin binding. IdeS/Mac-1 produced by serotype 1 S. pyogenes can inhibit neutrophil activation, phagocytosis, and the release of bactericidal reactive oxygen species (ROS) by binding the Fc receptor CD16/FcγRIIIB [43] .
Mac-2 ( Fig. 2 (C) ), an allelic variant of IdeS/Mac-1, differs by approximately 50% of amino acids localised to the middle one-third of the protein [46] . Mac-2 was originally believed to display weak endopeptidase activity, instead exerting its biological function primarily through binding to Fcγ receptors (FcγRII/CD32 and FcγRIII/ CD16) [46] . However, this weak enzymatic activity was shown to be an exception, specific to serotype M28 (Mac-2 M28 ) [47] . Using the enzymatically inert Mac-2 M28 , it was shown that the ability to inhibit ROS production, as a measure of phagocyte activation, was independent of the IgG endopeptidase activity [47] . However, the ROS inhibitory function of IdeS/Mac-1 and Mac-2 did not confer protection in a whole human immune blood infection model, while impairment of the IgG endopeptidase significantly reduced bacterial survival [47] .
EndoS is a secreted 108-kDa endoglycosidase that cleaves the chitobose core of the asparagine-linked glycan present on the heavy chain of native human IgG (Fig. 2  (D) ) [48] . Glycosylation at asparagine-297 is crucial for the interaction with Fcγ receptors displayed by phagocytic cells and IgG-mediated complement activation [49] . Pretreatment of IgG with recombinant EndoS significantly increased GAS survival in a human opsonophagocytic killing assay [50] . In spite of the evolutionary conserved nature of the ideS/mac and ndoS genes and their bifunctional nature in targeting antibodies and phagocytes, the mutagenesis of ideS or ndoS in the highly virulent M1T1 clone did not impair phagocyte resistance or pathogenicity in a systemic mouse model of infection [51, 52] . It remains to be seen whether ideS or ndoS expression in vitro correlates with that in vivo, and whether IdeS/ Mac-1 or EndoS is important in promoting virulence in other S. pyogenes serotypes and infection models.
Endopeptidase O
Recent work by Honda-Ogawa et al. [53] identified a novel secreted complement inhibitor, endopeptidase O (PepO). PepO is highly conserved in S. pyogenes and exhibits 68% amino acid sequence homology with Streptococcus pneumoniae PepO. In similar function to the pneumococcus PepO, GAS PepO binds to the CP activator, C1q (Fig. 2 (E) ). PepO binds to C1q in an electrostaticdependent fashion and inhibits the interaction of C1q with IgG under low pH conditions consistent with inflamed tissues. Although the authors did not show inhibition of the CP by PepO through conventional complement-activation assays, deletion of pepO did decrease bacterial growth in human serum at a low pH and resulted in reduced skin lesion size in murine infection models [53] . Given the importance of PepO in regulating SpeB expression [54] , future studies will be required to fully elucidate the mechanism played by PepO alone in complement evasion.
Inhibiting MAC Deposition
The cellular architecture of Gram-positive bacteria, namely the thick outer wall of peptidoglycan, prevents MAC-mediated lysis [55] . In spite of this, S. pyogenes expresses proteins that can interfere with MAC assembly either directly, mediated by the streptococcal inhibitor of complement (SIC) [56] , or indirectly, through the expression of vitronectin-binding proteins (VnBPs) [57] . SIC is a 31-kDa protein which can bind to C5b67 and C5b678 complexes (Fig. 2 (G) ), preventing MAC formation and incorporation into susceptible membranes [56] . VnBPs interact with vitronectin [57] which, in turn, inhibits MAC assembly at the C9 polymerisation stage (Fig. 1 (8) ). Additionally, both SIC and VnBPs have alternative roles that contribute to S. pyogenes pathogenicity, independent of MAC interference.
It is unclear if the inhibition of MAC formation is a by-product of a more important function of the 2 proteins or a pivotal mechanism to protect the bacteria. Although the MAC can deposit on the surface of S. pyogenes in distinct locations [58] , the role this has in mediating an immune response is not understood and clearly calls for further investigation to elucidate if the MAC affects bacteria physiology or somehow serves as a signalling molecule for the cells of the immune system.
Therapeutic Options
Better than treating an infection is preventing it. Thus, the obvious choice for therapy against S. pyogenes infection would be to vaccinate. Since 1796, when Edward Jenner performed the first vaccination, uncountable infections have been prevented and lives been saved. Unfortunately, to date, S. pyogenes has consistently resisted all efforts to develop a vaccine (reviewed in [59] ). The M protein has been considered a useful target since anti-M protein antibodies confer protection against streptococcal infections. However, due to molecular mimicry of the M protein, antibodies against this virulence determinant often react with host tissues and cause post-streptococcal acute glomerulonephritis and rheumatic fever [60] . Ideally, one vaccination should protect against as many different M serotypes of S. pyogenes as possible. However, due to its hypervariability at the N-terminus of the M protein, antibodies against M proteins are extremely serotype-specific and confer protection usually only against a single type [61] . This renders an DOI: 10.1159/000492944 M protein vaccine very inefficient. Nevertheless, the M protein has great potential as a vaccine candidate if these abovementioned were overcome.
Despite emerging resistance to antibiotics and the fear of entering a "post-antibiotic era", S. pyogenes is susceptible to most antibiotic classes including penicillin. However, if bacteria would develop a β-lactam resistance, for example, we would face a very serious situation with dramatic infection rates and high mortality. Thus, alternative approaches beyond conventional antibiotic therapy must be developed to cope with increasing infections.
Complement inhibitors C4BP and FH play a crucial role during S. pyogenes infections [10] . The presence of both inhibitors reduces the necessary inoculum to cause a systemic infection in an animal model by about 2 log 10 . Such an obvious influence raises the question if complement inhibitors could be a suitable target for a medical intervention.
Shaughnessy et al. [62, 63] designed a chimeric FHIgG protein, consisting of an IgG backbone fused to certain domains of FH known to bind to microbes. FH is a monomer with only 1 binding site, while fusing the FH domains to 1 heavy chain of IgG creates a molecule with 2 binding sites. This ensures a greater avidity of FH-IgG compared to serum FH. Consequently, they demonstrated the effectivity of this human fusion protein of experimental bacterial infections of Neisseria sp. The same effect of FH-IgG was also observed by a different group using H. influenzae [64] . Since complement can lyse and kill Gram-negative bacteria through pore formation, removing the protection conveyed by complement inhibitors will eventually cause the death of the bacteria. As discussed above, on Gram-positive bacteria, this does not occur. Using S. pyogenes as an example, we investigated if FH-IgG would have an antibacterial effect on Gram-positive bacteria as well. Indeed, we observed binding of FHIgG to the bacteria and a displacement of serum FH from the bacterial surface, leading to increased MAC deposition [22] . Increased killing, however, was not observed in serum sensitivity assays, but only when co-incubated in whole blood. The decrease of the bacterial blood burden was attributed to the presence of phagocytes. To our surprise, FH-IgG had nearly no effect on Fc-mediated phagocytosis but worked exclusively through enhanced opsonophagocytosis. This approach shows that complementbased therapeutics could play an important role in infection control in this era of dramatically increasing resistance to antibiotics.
Currently, there are several complement evasion molecules that hold promise as new vaccine candidates, displaying protection in mouse models of infection against important human pathogens. Recently, the B. pertussis autotransporter, Vag8, was used to immunise mice against subsequent respiratory infection [65] . Vag8 binds the complement regulatory C1 esterase inhibitor (C1-INH) [66] , thereby promoting the interaction and inactivation of both CP and LP serine proteases (C1r/s and MASP) to prevent complement activation. Vaccination with recombinant Vag8 resulted in a significant reduction in lung bacterial load, most likely through inhibiting this important complement surface evasin, thereby highlighting the potential use of complement evasins as vaccine targets.
Conclusions
Complement is one of the human body's first lines of defence and is crucial in preventing infections. Positive selection pushed bacteria to develop countermeasures to overcome complement attack. Looking at the different virulence factors, it is evident that all steps of complement activation are targets. This ensures that the bacteria can evade complement and even prevent further activation of immunity. There is evidence that recruiting human regulators could be a winning concept, especially C4BP and FH. About 2/3 of all serum protein-recruiting virulence factors bind FH and thus interfere with complement on the level of C3, preventing opsonisation and further immune activation. The amount of deposited C3b is a measure of complement activation and is proportional to the amount of released anaphylatoxins C3a and C5a, deposited membrane attack complex (MAC), and opsonophagocytosis. For the microbe, inhibiting complement early is an efficient evasive strategy, as, not only does it prevent C3b deposition (an "eat-me" signal for professional phagocytes), it also avoids anaphylatoxin release and subsequent immune activation and phagocyte recruitment to the infection site.
Besides the main goal of developing a protective vaccination, potential therapies could concentrate on complement and FH in particular. Not only one virulence factor would be addressed, but a key player for complement evasion in S. pyogenes would be approached. Up to now, S. pyogenes fortunately shows only few signs of antibiotic resistance. We should not feel safe, but rather immediately set to developing alternatives to prevent an ominous future where S. pyogenes infections would no longer be treatable. S. pyogenes is one of the most successful human pathogens, and clearly its vast arsenal of virulence factors has enabled it to cope with all immune defences of the human body.
